Vascular diseases

Tactile Medical to Present at the Guggenheim 2021 MedTech Disruptors Summit

Retrieved on: 
Wednesday, August 4, 2021

MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Guggenheim 2021 MedTech Disruptors Summit, which is being held virtually from August 9th-10th.

Key Points: 
  • MINNEAPOLIS, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of chronic diseases at home, today announced that management will participate in the Guggenheim 2021 MedTech Disruptors Summit, which is being held virtually from August 9th-10th.
  • Tactile Medical is a leader in developing and marketing at-home therapy devices that treat chronic swelling conditions such as lymphedema and chronic venous insufficiency.
  • Tactile Medicals Mission is to help people suffering from chronic diseases live better and care for themselves at home.
  • Tactile Medical takes pride in the fact that our solutions help increase clinical efficacy, reduce overall healthcare costs and improve the quality of life for patients with chronic conditions.

SkinTE® Met Primary and Secondary Endpoints in Final Analysis from Diabetic Foot Ulcer Trial

Retrieved on: 
Wednesday, July 28, 2021

The SkinTE plus SOC treatment group had 66 AEs allocated to 21 subjects while the SOC treatment group had 82 AEs allocated to 28 subjects.

Key Points: 
  • The SkinTE plus SOC treatment group had 66 AEs allocated to 21 subjects while the SOC treatment group had 82 AEs allocated to 28 subjects.
  • Wound size for the SkinTE plus SOC treatment group was 3.5 cm2 versus 3.2 cm2 for the SOC treatment group (p=0.46).
  • Additionally, PolarityTE announced a randomized controlled trial evaluating SkinTE versus SkinTE plus SOC in Venous Leg Ulcers (VLUs) has been completed with a total of 29 enrolled participants.
  • Topline data from the VLU trial will be announced via press release in the second half of 2021.

Balt Completes Enrollment in FIRST: A Multi-center, Prospective, International Study of Low Profile Silk Vista Flow Diverters

Retrieved on: 
Wednesday, July 28, 2021

The FIRST study is an observational, prospective, multi-center, international, single-arm study with the aim of collecting safety and efficacy information on the use of the Silk Vista and Silk Vista Baby flow diverter in order to continue to assess clinical safety and performance of the device for treating intracranial aneurysms.

Key Points: 
  • The FIRST study is an observational, prospective, multi-center, international, single-arm study with the aim of collecting safety and efficacy information on the use of the Silk Vista and Silk Vista Baby flow diverter in order to continue to assess clinical safety and performance of the device for treating intracranial aneurysms.
  • The study is designed to collect data for up tofive years, with the primary endpoint assessedat one year.
  • This international and multi-center study involves29 sitesworldwide: France, Germany, Austria, Belgium, Netherlands, Spain, Italy, Croatia, and Israel, with a largecohort of 234 patients.
  • For more information, please visit: https://www.balt-corp.com/
    The Silk Visa and the Silk Vista Baby are not available for sale in the US.

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 28, 2021

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

Branched Stent Grafts Market Size To Reach $477.5 Million By 2028: Grand View Research, Inc.

Retrieved on: 
Wednesday, July 28, 2021

SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, July 28, 2021 /PRNewswire/ -- The global branched stent grafts market size is anticipated to reach USD 477.53 million by 2028, registering a CAGR of 7.9% from 2021 to 2028, according to a new report by Grand View Research, Inc.
  • In addition, the preference for endovascular treatment for aortic aneurysms further boosts the market growth.
  • Thoracic aortic aneurysm and AAA are types of aortic aneurysms; aneurysms can also occur in other parts of the body.
  • Grand View Research has segmented the global branched stent grafts market on the basis of type, application, and region:
    Branched Stent Grafts Type Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)
    Branched Stent Grafts Application Outlook (Volume, Units; Revenue, USD Million, 2021 - 2028)

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

Retrieved on: 
Friday, July 23, 2021

The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .

Key Points: 
  • The first patients, who were under the care of principal investigator, Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee, were successfully implanted with the CGuard EPS stent device .
  • These are the first of 315 patients who are expected to be enrolled in the trial and treated with CGuard EPS in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting.
  • I believe that the initiation of this trial marks an important milestone for the potential approval of CGuard EPS and the potential of CGuard EPS in advancing the treatment of CAD and stroke prevention, commented Dr. Metzger.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

KANEKA CORPORATION: Sales Expansion of Brain Aneurysm Embolization Coils in the United States

Retrieved on: 
Friday, July 9, 2021

Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.

Key Points: 
  • Inc., Kaneka intends to further expand the sales in the U.S. market from August 2021.
  • Kaneka Medical America has been promoting the product at major stroke centers in the U.S., the worlds largest market.
  • It is deployed into the aneurysm through a catheter to prevent blood flow into the aneurysm.
  • A brain aneurysm is a bump that develops in an artery of the brain, and if it ruptures, it can cause subarachnoid hemorrhage.

First Ever Standard Surgical Risk Patient TCAR Data to be Presented at the Society for Vascular Surgery 2021 Vascular Annual Meeting

Retrospective data for symptomatic and asymptomatic standard risk patients undergoing CEA and TCAR for atherosclerotic carotid disease was reviewed to show TCAR and CEA have equivalent risk of perioperative stroke, death, or MI and ipsilateral stroke through 1 year.

Key Points: 
  • Retrospective data for symptomatic and asymptomatic standard risk patients undergoing CEA and TCAR for atherosclerotic carotid disease was reviewed to show TCAR and CEA have equivalent risk of perioperative stroke, death, or MI and ipsilateral stroke through 1 year.
  • We are thrilled to have this ground-breaking analysis presented at VAM, the preeminent annual Vascular Surgery conference.
  • In addition to this presentation, Silk Road Medical will be hosting TCAR @ Vascular Live at the Vascular Annual Meeting on Friday, August 20 from 3:05-3:30 p.m. PDT in Exhibit Hall B1.
  • Silk Road Medical will be exhibiting at the Society for Vascular Surgerys Vascular Annual Meeting in booth #401.

Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited

Retrieved on: 
Tuesday, July 6, 2021

The transaction expands Surmodics thrombectomy portfolio with a second U.S. Food and Drug Administration (FDA) 510(k)-cleared device, the ReVene Thrombectomy Catheter.

Key Points: 
  • The transaction expands Surmodics thrombectomy portfolio with a second U.S. Food and Drug Administration (FDA) 510(k)-cleared device, the ReVene Thrombectomy Catheter.
  • Surmodics is now well positioned with two ground-breaking, FDA-cleared mechanical thrombectomy devices to treat both arterial and venous thrombosis.
  • Under the terms of the acquisition agreement, Surmodics acquired Vetex with an upfront payment of $39.9 million.
  • Surmodics plans to provide updated fiscal 2021 guidance, including the impact from the Vetex acquisition, during its third quarter earnings announcement.

Endovascular Aneurysm Repair (EVAR) Market Report 2021: Global Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021

The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endovascular Aneurysm Repair (EVAR) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global endovascular aneurysm repair market exhibited moderate growth during 2015-2020.
  • Looking forward, the global endovascular aneurysm repair market to grow at a CAGR of around 5% during the forecast period (2021-2026).
  • Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers.